1-8 of 8
Yan Wu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Novel Anti-LY6G6D/CD3 T-Cell–Dependent Bispecific Antibody for the Treatment of Colorectal Cancer

Peiyin Wang, Liping L. Sun, Robyn Clark, Maria Hristopoulos, Cecilia P.C. Chiu, Michael Dillon, WeiYu Lin, Amy A. Lo, Sreedevi Chalsani, Meghna Das Thakur, Kristin M. Zimmerman Savill, Lionel Rougé, Patrick Lupardus, Robert Piskol, Bushra Husain, Diego Ellerman, Vittal Shivva, Steven R. Leong, Meric Ovacik, Klara Totpal, Yan Wu, Christoph Spiess, Genee Lee, Douglas D. Leipold, Andrew G. Polson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2022) 21 (6): 974–985.
https://doi.org/10.1158/1535-7163.MCT-21-0599
Published: 01 June 2022
View article titled, Novel Anti-LY6G6D/CD3 T-Cell–Dependent Bispecific Antibody for the Treatment of Colorectal Cancer
Open the PDF for Novel Anti-LY6G6D/CD3 T-Cell–Dependent Bispecific Antibody for the Treatment of Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract P001: The anti-angiogenic antibody BD0801 demonstrates better anti-tumor activity than bevacizumab and synergize with chemotherapies in multiple tumor models

Liting Xue, Jianxing Tang, Yuyin Ding, Lei Song, Shansen Xu, Yue Huang, Yan Wu, Wenjie Song, Renhong Tang, Wenqing Yang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (12_Supplement): P001.
https://doi.org/10.1158/1535-7163.TARG-21-P001
Published: 01 December 2021
View article titled, Abstract P001: The anti-angiogenic antibody BD0801 demonstrates better anti-tumor activity than bevacizumab and synergize with chemotherapies in multiple tumor models
Journal Articles

Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer

Amy A. Lo, Jennifer Johnston, Ji Li, Danielle Mandikian, Maria Hristopoulos, Robyn Clark, Dorothee Nickles, Wei-Ching Liang, Kathy Hötzel, Debra Dunlap, Thinh Pham, Hao Cai, Meric Ovacik, Daniel Bravo-Perez, Elaine Mai, Dionysos Slaga, Diego Ellerman, James Ziai, Klara Totpal, Genee Lee, C. Andrew Boswell, Jian Payandeh, Yan Wu, Teemu T. Junttila
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (4): 716–725.
https://doi.org/10.1158/1535-7163.MCT-20-0490
Published: 01 April 2021
View article titled, Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer
Open the PDF for Anti-LYPD1/CD3 T-Cell-Dependent Bispecific Antibody for the Treatment of Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract C173: Anti-PD-L1 antibody-based IL-15 immunocytokine has enhanced antitumor immunity

Yan Wu, Zhaojing Zhong, Stella Martomo, Dan Lu, Zhanna Polonskaya, Xenia Luna, Haifan Zhang, Zhikai Zhang, Zhun Wang, Leo Liu, Jeegar Patel, James Tonra, Henry Li, Larry Witte, Sam Waksal, Zhenping Zhu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C173.
https://doi.org/10.1158/1535-7163.TARG-15-C173
Published: 01 December 2015
View article titled, Abstract C173: Anti-PD-L1 antibody-based IL-15 immunocytokine has enhanced antitumor immunity
Journal Articles

Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity

Yiyuan Yin, Stevan Djakovic, Scot Marsters, Janet Tien, Jing Peng, Jarrod Tremayne, Genee Lee, Richard M. Neve, Yan Wu, Mark Merchant, Avi Ashkenazi, Paul J. Carter
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2015) 14 (10): 2270–2278.
https://doi.org/10.1158/1535-7163.MCT-14-1050
Published: 05 October 2015
View article titled, Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity
Open the PDF for Redesigning a Monospecific Anti-FGFR3 Antibody to Add Selectivity for FGFR2 and Expand Antitumor Activity in another window
Includes: Supplementary data
Journal Articles

Enhanced Chemotherapy of Cancer Using pH-Sensitive Mesoporous Silica Nanoparticles to Antagonize P-Glycoprotein–Mediated Drug Resistance

I-Ping Huang, Shu-Pin Sun, Shih-Hsun Cheng, Chia-Hung Lee, Chia-Yan Wu, Chung-Shi Yang, Leu-Wei Lo, Yiu-Kay Lai
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (5): 761–769.
https://doi.org/10.1158/1535-7163.MCT-10-0884
Published: 08 May 2011
View article titled, Enhanced Chemotherapy of Cancer Using pH-Sensitive Mesoporous Silica Nanoparticles to Antagonize P-Glycoprotein–Mediated Drug Resistance
Open the PDF for Enhanced Chemotherapy of Cancer Using pH-Sensitive Mesoporous Silica Nanoparticles to Antagonize P-Glycoprotein–Mediated Drug Resistance in another window
Includes: Supplementary data
Journal Articles

Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake

Yonglei Shang, Yifan Mao, Jennifer Batson, Suzie J. Scales, Gail Phillips, Mark R. Lackner, Klara Totpal, Simon Williams, Jihong Yang, Zhijun Tang, Zora Modrusan, Christine Tan, Wei-Ching Liang, Siao Ping Tsai, Alexander Vanderbilt, Kenji Kozuka, Klaus Hoeflich, Janet Tien, Sarajane Ross, Congfen Li, Sang Hoon Lee, An Song, Yan Wu, Jean-Philippe Stephan, Avi Ashkenazi, Jiping Zha
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (9): 2599–2608.
https://doi.org/10.1158/1535-7163.MCT-07-2401
Published: 11 September 2008
View article titled, Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake
Open the PDF for Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake in another window
Includes: Supplementary data
Journal Articles

Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target

Nick Loizos, Yan Xu, Jim Huber, Meilin Liu, Dan Lu, Bridget Finnerty, Robin Rolser, Asra Malikzay, Anita Persaud, Erik Corcoran, Dhanvanthri S. Deevi, Paul Balderes, Rajiv Bassi, Xenia Jimenez, Christopher J. Joynes, Venkata R.M. Mangalampalli, Philipp Steiner, James R. Tonra, Yan Wu, Daniel S. Pereira, Zhenping Zhu, Dale L. Ludwig, Daniel J. Hicklin, Peter Bohlen, Larry Witte, Paul Kussie
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (3): 369–379.
https://doi.org/10.1158/1535-7163.MCT-04-0114
Published: 14 March 2005
View article titled, Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target
Open the PDF for Targeting the platelet-derived growth factor receptor α with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: Implications as a potential therapeutic target in another window